AC Immune
ACIU
31 hedge funds and large institutions have $47.4M invested in AC Immune in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
587% more call options, than puts
Call options by funds: $838K | Put options by funds: $122K
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
44% more capital invested
Capital invested by funds: $33M → $47.4M (+$14.4M)
2.31% more ownership
Funds ownership: 16.86% → 19.17% (+2.3%)
9% less funds holding
Funds holding: 34 → 31 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$5.63M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$524K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$356K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$137K |
| 5 |
Two Sigma Investments
New York
|
+$33.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2.04M |
| 2 |
Morgan Stanley
New York
|
-$420K |
| 3 |
Millennium Management
New York
|
-$147K |
| 4 |
E
Ergoteles
New York
|
-$46.8K |
| 5 |
Mariner
Overland Park,
Kansas
|
-$34K |
ACIU Hedge Fund Activity: Q2 2023 in Review
31 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q2 2023, worth a combined $47.4M — up 44% from $33M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACIU and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Avidity Partners Management, adding an estimated $5.63M. The largest seller was Citigroup, exiting entirely with an estimated $2.04M sold.
- 31 institutional investors held AC Immune (ACIU) as of Q2 2023, down from 34 in Q1 2023.
- Funds reported $47.4M of AC Immune stock for Q2 2023, up 44% quarter-over-quarter.
- 4 funds opened new AC Immune positions in Q2 2023 and 7 closed out, a net change of -3 holders.
- The largest AC Immune buyer in Q2 2023 was Avidity Partners Management, an estimated $5.63M added.
- The largest AC Immune seller in Q2 2023 was Citigroup, an estimated $2.04M sold.
Based on aggregated 13F filings for Q2 2023.